key: cord-0783551-ke94njve
authors: Nayak, Saurabh; Bharati, Joyita
title: Corticosteroids and COVID-19: What Could Be the Best Bet in Treating Active Glomerular Diseases in Patients With Concomitant Early COVID-19?
date: 2020-09-28
journal: Am J Kidney Dis
DOI: 10.1053/j.ajkd.2020.09.006
sha: ae1f9d885a00f49a1342d73e629475a44cf80c92
doc_id: 783551
cord_uid: ke94njve

nan

antiviral agent could be done. We believe more data with antiviral therapy will emerge as trials include patients with kidney disease. Not least of all, shared decision making with the patient must be done after explaining possible benefits and harms of treatment.

Support: None.

Financial Disclosure: The authors declare that they have no relevant financial interests.

Peer Review: Received August 26, 2020. Direct editorial input from an Associate Editor and a Deputy Editor. Accepted in revised form September 15, 2020.

High-dose but Not Low-dose Corticosteroids Potentially Delay Viral Shedding of Patients With COVID-19

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

A Narrative Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19

COVID-19: implications for immunosuppression in kidney disease and transplantation